For further information on the following projects, please contact the company's CEO, Directors or Project Managers below. 



ActiveTorque Pty Ltd - Real time tuning of internal combustion engines

ActiveTorque is commercialising an innovative engine management technology that has the potential to significantly reduce greenhouse gas and toxic emissions from motor vehicle engines.  The ActiveTorque system utilises its patented LEO technology (Lerning Extremum Optimisation) to dynamically calculate the optimal engine operating settings, adapting to changing operating conditions as they occur.  This novel approach to engine control optimises the performance of standard combustion engines to achieve maximum possible engine efficiency, without risking damage to the engine.

Contact Director:  Dr Peter Devine
Website:  www.activetorque.com.au

- - - - - - - - - - - - - - - - - - - - -

BT Imaging Pty Ltd  - In-line Luminescence Imaging for photovoltaic cells

BT Imaging technology is based on in line luminescence imaging of silicon wafers and solar cells as a means of quality control.  This technology offers a superior method for the inspection of silicon wafers and offers manufacturers of the wafers significant throughput, performace and cost advantages.  The development is well advanced and market opportunity is suppported by interest from a number of firms.  Existing production-line inspection techniques for wafers are performed only late in the manufacturing process when current-voltage characteristics of each complete cell can be measured using contracting instruments.  Costs could be significantly lowered and product quality enhanced if inspections were possible throughout the production process.  The inventors have produced a functional prototype system that has been used frequently for consulting work.

Contact CEO:  Ian Maxwell
Website:  www.btimaging.com
go to top

- - - - - - - - - - - - - - - - - - - - -

Continence Control Systems International Pty Ltd - devices for urinary and faecal incontinence 

CCS is developing a device to aid colostomy patients in managing their stomas (formerly Uniseed investee Colocare) and a surgical procedure for urinary incontinence based on electrical stimulation of smooth muscle grafts.  Both technologies are currently under clinical evaluation.

Contact CEO:  Tony Stephens
Website: www.colocare.com.au
go to top

- - - - - - - - - - - - - - - - - - - - -

Cryptopharma Pty Ltd - Novel Anti-Inflammatory Therapeutics

Cryptopharma is a startup company dedicated to developing therapeutic treatments for anti-tumour and anti-inflammatory indications.  Initial developments have centred on analogues of 2-methoxyestradiol (2MEO). The company has developed a family of compounds which are highly potent and selective inhibitors of smooth muscle cell proliferation, and which have demonstrated anti-asthmatic activity in in-vivo mouse models. It is believed that these compounds represent a totally novel therapeutic approach to treating inflammatory diseases such as asthma and cystic fibrosis.

Contact Project Manager: David Crump
Website: www.cryptopharma.com
go to top

- - - - - - - - - - - - - - - - - - - - -

Fultec Semiconductor Inc- Protection of Electronic Circuits

Fultec has developed a technology for protecting electronic circuits from electrical power surges such as those from lightning strikes. The Uniseed investment is to develop the discrete device ready for sale. The device is a protection switch that virtually instantaneously disconnects vulnerable equipment from the disturbed input power terminal and then reconnects the system after the surge has passed. The device offers simpler, cheaper and higher performance protection than existing shunt protection devices which impact the performance of sensitive circuits (such as communications equipment) and limit circuit bandwidth because of circuit loading. The Co-Investors are Crescendo Ventures USA, Mayfield Ventures USA, ComVentures USA and Allen & Buckeridge.

Contact CEO: Mr Peter Brooks
Website:  www.fultec.com
go to top

- - - - - - - - - - - - - - - - - - - - -

Hatchtech Pty Ltd - Low Toxicity Insecticides

Hatchtech is a start-up company that builds on the expertise of staff at the University of Melbourne's Centre for Animal Biotechnology to develop a new generation of low-toxicity ovacides for human parasites. The protected methodologies of Hatchtech involve identification, and selective inhibition of key processes involved in egg hatching. The company is focused on human headlice and agricultural application of the technology, with the human application currently in Phase II trials under an IND with the US FDA.

Contact CEO: Dr Paul MacLeman 
Website: www.hatchtech.com.au
go to top

- - - - - - - - - - - - - - - - - - - - -

Neurotide is developing the next generation of pain killers based on the body's own natural pain killer, endomorphin. Synthesised endomorphin can relieve pain when delivered directly to the brain, but has a short life span and is unsuitable as a drug without modifications. Neurotide is developing an orally available form of endomorphin for the treatment of chronic and acute pain as well as a new treatment for neuropathic pain, which can be caused by diabetes, injury and certain infections.

Contact Director: Dr Peter Devine
Website: www.neurotide.com
go to top

- - - - - - - - - - - - - - - - - - - - -

OPAL Therapeutics is investigating a novel, simple and easy to administer vaccine for HIV and HCV. The  OPAL technique boosts the immune system's ability to fight chronic infections and should delay the onset of AIDS in HIV-infected patients.  Having completed primate studies, OPAL plans to take the treatment through Phase I human clinical trials.

Chief Executive Officer: Mr Mark Sullivan
go to top

- - - - - - - - - - - - - - - - - - - - -

Pepfactants Pty Limited - Smart Peptide Surfactants

Pepfactants R are purpose designed peptide surfactants with the potential to revolutionise the control of emulsions and foams in industrial processes.  their properties allow them to be recovered and recycled - providing enormous cost savings to industry.  also, they are a sutainable, biodegradable and environmentally friendly alternative.  However, the key feature of the peptides is their novel ability to make and break emulsions and foams reversible on demand.  this disruptive technology will impact a myriad of large and economically important markets ranging from the petroleum to the cosmetic and processed food industries.

Contact Director:  Mr Richard Marshall
go to top


- - - - - - - - - - - - - - - - - - - - -

QRxPharma Pty Ltd - Novel Thrombotic Drug Leads & Pain Therapies

QRx was formed in late 2002 with initial venture capital backing led by Innovation Capital (Australia and US), Nanyang Ventures (Australia), SpringRidge Ventures (US) and UniSeed (Australia) and listed on the ASX in May 2007.   The Company has a development pipeline that includes a combination pain therapy in Phase III clinical trials, with others in preclinical development and discovery. 

Email: business@qrxpharma.com
Website: www.qrxpharma.com
go to top

- - - - - - - - - - - - - - - - - - - - -

Spinifex Pharmaceuticals Pty Limited - Novel solutions for the treatment of pain

Spinifex has received approval to progress to Investigational New Drug (IND) enabling studies for its lead neuropathic pain drug EMA-401 under the guise of the US FDA.

Contact CEO: Dr Tom McCarthy
Website: www.spinifexpharma.com.au
go to top

- - - - - - - - - - - - - - - - - - - - -

Velacor Therapeutics Pty Limited - A novel approach to cancer treatment

Velacor is developing a novel treatment for prostate cancer through inhibition of the protein kinase Akt pathway. The technology will target the growing prostate cancer market, currently valued at $2.1 billion, serviced by largely ineffective treatments. Velacor has demonstrated selective inhibition of the protein kinase Akt pathway in vivo, a pathway known to play a key role in the augmentation and development of a range of cancers, including prostate, glioblastoma, ovarian and lung cancer. Velacor has recently completed Phase I clinical trials.

Contact CEO :  Ms Vanessa Waddell
go to top

- - - - - - - - - - - - - - - - - - - - -

Verva Pharmaceuticals Limited  - 'Targeting Obesity' (formerly Adipogen)

Verva was formed in December 2007 by the merger of Uniseed investee Adipogen Pharmaeuticals with Autogen research (the metabolic diseases focused subsidiary of ChemGenex Pharmaceuticals).  Verva's lead clinical product VVP808, an insulin sensitizer for use in Type 2 diabetes, will enter phase 1b/2a clinical testing in 2008.  In addition, Verva is utilizing its discovery engine to identify novel small molecule insulin secretion modulators, thus expanding the Company's diabetes therapeutic range and product options.  Verva's core obesity technologies involve the modulation of fibroblast growth factor-1 (FGF-1) signalling and inosine-5' monophosphate dehydrogenase (IMPDH) activity to alter fat cell formation.  Preclinical in vivo proof of concept has been achieved with both technologies.

Contact CEO: Dr Vince Wacher
Website: www.vervapharma.com
go to top

- - - - - - - - - - - - - - - - - - - - -

Xerocoat Pty Limited - Anti-fogging and anti-reflective coating technology

Xerocoat is developing coating technology to create anti-fogging and anti-reflective properties on a number of surfaces. The technology is being applied to improving the performance of solar cells.   The novel approach also has application in a variety of consumer products such as reading and sun glasses; sporting eyewear such as swimming goggles; or flat glass products such as mirrors and windscreens. The technology's anti-reflective property has the potential to improve the performance of electronic products such as touch screens,and glasshouses.

Contact CEO: Thomas Hood
Website: www.xerocoat.com
go to top

- - - - - - - - - - - - - - - - - - - - -

To discuss any of the above Uniseed investments, please contact the investee company's CEO, Director or project manager listed above, or the Uniseed CEO.

Dr Peter Devine
CEO
Uniseed Management Pty Ltd
Level 7, GP South, Bldg (78)
Staff House Road
University of Queensland
St Lucia. Queensland. 4072
Australia

Phone: 61-(0)7-3365 6937
Fax: 61-(0)7-3365 4433
Email: